Pfizer PFE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenues: by Product | ||||||
| Abrysvo | $180M+37.4% | $480M+142% | $279M-21.6% | $143M+155% | $131M-9.7% | |
| Adcetris | $190M-12.8% | $220M-22.8% | $215M-19.8% | $255M-8.6% | $218M-15.2% | |
| All Other Hospital and Biosimilars | $953M+5.8% | —— | —— | —— | $901M— | |
| All other Oncology | $376M-0.3% | $303M+6.3% | $272M+1.5% | $380M+9.5% | $377M+25.2% | |
| All other Primary Care | $654M+7.4% | $789M+0.3% | $721M-2.8% | $736M-3.0% | $609M-20.9% | |
| All other Specialty Care | $579M+19.1% | $476M+38.4% | $407M+26.0% | $390M-9.1% | $486M-5.3% | |
| Bosulif | $129M-14.6% | $161M-5.8% | $150M-6.8% | $149M-10.8% | $151M+4.1% | |
| Braftovi/Mektovi | $174M+27.9% | $197M+15.9% | $202M+16.8% | $182M+23.0% | $136M+17.2% | |
| Cibinqo | $76M+31.0% | $78M+23.8% | $79M+25.4% | $69M+46.8% | $58M+38.1% | |
| Comirnaty | $232M-58.9% | $2.27B-32.9% | $1.15B-19.1% | $381M+95.4% | $565M+59.6% | |
| Eliquis | $2.17B+12.6% | $2.02B+10.3% | $2.02B+24.6% | $2B+6.7% | $1.92B-5.7% | |
| Elrexfio | $80M+33.3% | $74M+29.8% | $85M+113% | $85M+286% | $60M+362% | |
| Enbrel (Outside the U.S. and Canada) | $138M-1.4% | $179M-2.2% | $154M-8.9% | $154M-14.0% | $140M-11.9% | |
| FSME-IMMUN/TicoVac | $81M+28.6% | $47M+38.2% | $100M+23.5% | $109M+9.0% | $63M-3.1% | |
| Genotropin | $93M-2.1% | $117M+4.5% | $128M+7.6% | $106M-10.9% | $95M-20.8% | |
| Ibrance | $1.01B+3.2% | $1.04B-5.1% | $1.06B-2.8% | $1.05B-7.2% | $977M-7.3% | |
| Inflectra | $182M+19.0% | —— | $173M+37.3% | $139M+43.3% | $153M-3.2% | |
| Inlyta | $214M-2.3% | $235M-2.9% | $226M-8.5% | $243M-3.6% | $219M-7.6% | |
| Lorbrena | $305M+37.4% | $282M+46.1% | $268M+30.1% | $251M+48.5% | $222M+35.4% | |
| Nurtec ODT/Vydura | $353M+42.3% | $405M+3.1% | $412M+22.3% | $359M+0.8% | $248M+39.3% | |
| Octagam | $122M+38.6% | $120M+10.1% | $113M-48.9% | $97M-6.7% | $88M+17.3% | |
| Oncology Biosimilars | $409M+54.9% | $369M+76.6% | $315M+10.5% | $353M+26.5% | $264M0.0% | |
| Orgovyx | $109M+43.4% | $136M+109% | $112M+96.5% | $97M— | $76M— | |
| Padcev | $591M+38.7% | $508M+14.4% | $464M+13.4% | $542M+37.6% | $426M+24.9% | |
| Paxlovid | $186M-62.1% | —— | $1.23B-54.7% | $427M+70.1% | $491M-75.9% | |
| Pfizer CentreOne | $289M+5.9% | $409M+25.5% | $344M+20.7% | $328M+18.0% | $273M+5.8% | |
| Prevnar Family | $1.69B+1.8% | $1.71B+9.6% | $1.74B-3.4% | $1.38B+1.8% | $1.66B-1.8% | |
| Sulperazon (Outside the U.S. and Canada) | $199M+21.3% | $169M0.0% | $154M-1.3% | $166M+15.3% | $164M-1.8% | |
| Talzenna | $50M+25.0% | $49M+88.5% | $47M+30.6% | $46M+43.8% | $40M+73.9% | |
| Tivdak | $33M0.0% | $32M-13.5% | $37M+8.8% | $46M+39.4% | $33M+17.9% | |
| Tukysa | $122M+19.6% | $119M-7.8% | $110M-11.3% | $132M+9.1% | $102M-3.8% | |
| Vyndaqel family | $1.6B+7.8% | $1.69B+9.3% | $1.59B+10.0% | $1.62B+22.1% | $1.49B+30.7% | |
| Xeljanz | $180M+40.6% | $324M-7.4% | $313M-2.5% | $322M+6.3% | $128M-34.0% | |
| Xtandi | $444M-3.1% | $592M+4.8% | $578M+3.0% | $566M+14.3% | $458M+9.6% | |
| Zavicefta (Outside the U.S. and Canada) | $150M+11.1% | $181M+13.8% | $158M+3.9% | $163M+8.7% | $135M+8.0% | |
| Zithromax | $112M-29.1% | $113M-8.1% | $73M-12.0% | $56M-24.3% | $158M-21.0% | |
| Indefinite-lived intangible assets, period increase (decrease) by Product | ||||||
| Tukysa | -$580M— | —— | —— | —— | —— | |
| Revenues: by Geography | ||||||
| International Developed Markets | $3.43B+7.8% | $5.92B-5.8% | $3.7B+8.3% | $3.39B+7.2% | $3.18B-0.6% | |
| International Emerging Markets | $2.29B+6.0% | $2.52B+11.4% | $2.27B+1.8% | $2.37B+6.2% | $2.16B-0.2% | |
| U.S. | $8.73B+4.3% | $9.12B-1.1% | $10.69B-11.4% | $8.89B+12.7% | $8.37B-12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
